| Today’s Big NewsJun 2, 2025 |
| By Nick Paul Taylor Bristol Myers Squibb is paying BioNTech $3.5 billion to board the PD-1/L1xVEGF-A bandwagon. The deal, which features up to $7.6 billion in milestones, gives BMS a 50% stake in one of the leading candidates in the hottest area of immuno-oncology. |
|
|
|
By James Waldron AstraZeneca has produced data to back up its blockbuster ambitions for camizestrant, tying the oral SERD to a 56% improvement in progression-free survival in a phase 3 breast cancer study. |
By Gabrielle Masson The first half of this year been riddled with market volatility and geopolitical tension. But 2025’s American Society of Clinical Oncology conference largely isn’t reflecting that turmoil. |
Sponsored by Marken, UPS Healthcare Precision Logistics Radiopharma is revolutionizing modern medicine. Discover how precision logistics empowers faster, safer delivery of life-impacting therapies when every second counts. |
|
From gene therapy pipelines to early-stage VC deals, biotech leaders are seeking clarity in the chaos. That’s why companies are sharing their insights through Fierce content hubs — with weekly features right here in your inbox. See how others are shaping the narrative.
|
|
By Nick Paul Taylor Johnson & Johnson has shared more data on its multifront attack on KLK2, linking a bispecific antibody to 7.9 months progression-free survival in hard-to-treat prostate cancer patients. |
Sponsored by WCG When clinical trial steps are managed separately, the study suffers from compounded delays. Discover proven solutions from trusted industry experts. |
By James Waldron Regeneron is paying Hansoh Pharma $80 million upfront for a phase 3-stage GLP-1/GIP receptor agonist the companies believe can hold its own against Eli Lilly’s Zepbound. |
Sponsored by Bayer Discover how Bayer and BlueRock are redefining biotech partnerships. From breakthrough Parkinson’s therapies to a unique “arm’s-length” model, this episode of The Top Line dives into what makes their collaboration a blueprint for the future. |
By Gabrielle Masson Bicara Therapeutics has unveiled updated data for its bifunctional antibody paired with Keytruda in head and neck cancer, including a first look at overall survival data for HPV-negative patients as the biotech enrolls for a pivotal trial in the indication. |
Sponsored by Thermo Fisher Scientific Austin Read of Thermo Fisher Scientific discusses how combining biospecimens with real-world data is advancing diagnostics, treatment and the future of patient care. |
By Gabrielle Masson Immatics’ cell therapy has been linked to a 56% objective response rate among 32 heavily pretreated patients with metastatic melanoma. |
By James Waldron Actuate Therapeutics has set its sights on getting elraglusib approved for pancreatic cancer after the glycogen synthase kinase‐3 beta (GSK-3β) drug showed a three-month survival increase in a phase 2 study. |
By James Waldron Sanofi’s collaboration with Nurix is continuing to bear fruit, with the French pharma securing its second protein degrader program from the biotech in a matter of months. |
By Gabrielle Masson Kite Pharma’s bicistronic CAR T-cell therapy hit the main goal of a phase 1a trial, with zero dose-limiting toxicities occurring in patients with advanced B-cell lymphoma. The therapy was also tied to a complete response rate of 78% for patients receiving the highest cell therapy dose. |
By Conor Hale The companies that make up this class of the Fierce 15 exemplify the idea of moving the field forward by using innovation to build upon what’s come before. |
By Gabrielle Masson,Darren Incorvaia,James Waldron The Fierce Biotech Fundraising Tracker records venture capital rounds of $50 million or more secured by biotechs. |
By Eric Sagonowsky Moderna has picked up its third FDA approval with the agency's endorsement of mNEXSPIKE. The approval covers the vaccine's use in people 65 and older and those ages 12 to 64 with risk factors for severe COVID. |
By Zoey Becker Black women remain underrepresented in clinical trials for triple negative breast cancer, but distance to the sites may not be the main reason. |
Fierce podcastsDon’t miss an episode |
| | This week on "The Top Line," we break down first-quarter Big Pharma earnings, recap the latest gene therapy developments and preview what’s ahead at ASCO. |
|
|---|
|
|
| WhitepaperWe analyzed ~300 launches to identify the factors most correlated with commercial success & built a framework for peak go-to-market performance. Presented by Blue Matter, strategic consultants in the life sciences |
| |
|
